文献速递瘢痕与激光创面修复

儿童瘢痕治疗:切线切除联合病灶内注射与激光辅助5-FU递送

Pediatric Scar Management Using Tangential Excision With Intralesional Injections and Laser-Assisted 5-Fluorouracil Delivery.
PubMed 文献 · Ann Plast Surg · 2025-01-01

多机构回顾性研究纳入108例≤17岁瘢痕患者,比较CO2激光辅助5-FU递送或切线切除联合立即/延迟5-FU/曲安奈德注射的疗效与风险。切线切除联合5-FU单药可降低瘢痕高度并改善整体质量,并发症率无显著差异,无全身并发症。

要点

  • 切线切除联合5-FU单药较联合曲安奈德降低瘢痕高度(P<0.05,Δ=-0.5878)。
  • 切线切除联合<4次注射改善总瘢痕质量评分(n=44,Δ=-0.581)。
  • 各方案并发症率与复发率无显著差异,无全身并发症。

核心结论

  • 切线切除联合5-FU单药显示更低的瘢痕高度和更好的整体瘢痕质量。
  • CO2激光辅助5-FU递送并发症率与其他研究模态相似。
  • 本儿童研究无全身并发症,总体并发症率与成人研究相似。

研究设计与样本

  • 多机构回顾性研究,2012至2023年,纳入108例年龄≤17岁接受CO2激光辅助5-FU递送或切线切除联合立即/延迟5-FU/曲安奈德注射的患者。
  • 采用改良瘢痕评定量表评估个体瘢痕结局,比较5-FU单药 vs 曲安奈德、切线切除联合立即 vs 延迟注射、注射次数高于/低于中位数4次。
  • 采用Mann-Whitney U检验确定显著性,Fisher精确检验比较并发症率和复发率。

主要发现

  • 总瘢痕质量评分改善(P<0.05):切线切除联合<4次注射(n=44;Δ=-0.581)和切线切除联合5-FU单药(n=39;Δ=-0.775)。
  • 切线切除联合5-FU单药较联合曲安奈德(n=46)降低瘢痕高度(P<0.05;Δ=-0.5878)。
  • 颜色匹配改善(P<0.05):切线切除联合<4次注射(Δ=-0.449)和切线切除联合延迟注射(n=29;Δ=-0.380)。
  • 切线切除联合任何5-FU使用(n=62)并发症率4.84%,高于切线切除联合仅曲安奈德(n=30;0%)或切线切除联合5-FU单药(n=37;5.41%),但并发症率无显著差异。
  • CO2激光辅助5-FU(n=16)并发症率6.25%,与切线切除联合5-FU或曲安奈德无显著差异;无全身并发症;各组复发率无显著差异。

关键数值与推荐

  • 总瘢痕质量评分改善:切线切除联合<4次注射(n=44;Δ=-0.581,P<0.05);切线切除联合5-FU单药(n=39;Δ=-0.775,P<0.05)。
  • 瘢痕高度降低:切线切除联合5-FU单药较联合曲安奈德(n=46)(P<0.05;Δ=-0.5878)。
  • 颜色匹配改善:切线切除联合<4次注射(Δ=-0.449,P<0.05);切线切除联合延迟注射(n=29;Δ=-0.380,P<0.05)。
  • 并发症率:切线切除联合任何5-FU使用(n=62)4.84%;切线切除联合仅曲安奈德(n=30)0%;切线切除联合5-FU单药(n=37)5.41%;CO2激光辅助5-FU(n=16)6.25%;均无显著差异。
  • 复发率:所有组间无显著差异。

临床怎么用

  • 儿童瘢痕管理中,切线切除联合5-FU单药可能降低瘢痕高度并改善整体质量。
  • CO2激光辅助5-FU递送并发症率与其他研究模态相似,可作为治疗选择。
  • 5-FU在儿童瘢痕治疗中显示效用,无全身并发症,总体并发症率与成人研究相似。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric hypertrophic and keloid scars have traditionally been treated via intralesional steroid injections. The advent of modalities such as 5-fluorouracil (5-FU) and tangential excision present opportunities for improved therapy; however, 5-fluorouracil (5-FU) safety and efficacy in the pediatric population are not well established. The aim of this study is to compare the risk and efficacy of 5-FU in pediatric scar management. METHODS: A multi-institution retrospective study from 2012 to 2023 was designed with identification of 108 patients aged ≤17, undergoing CO2 laser-assisted 5-FU delivery, or tangential excision with immediate or delayed 5-FU/triamcinolone injections. Modified Scar Rating Scale assessed individual scar outcomes comparing the following groups: 5-FU alone versus triamcinolone use; tangential excision with immediate versus delayed injections; and number of injections above/below the median of 4 episodes of injections. Mann-Whitney U test determined significance. Fisher exact test compared complication and recurrence rates. RESULTS: Total scar quality scores improved (P < 0.05) with tangential excision plus <4 injections (n = 44; Δ = -0.581) and tangential excision with 5-FU only (n = 39; Δ = -0.775). Tangential excision with 5-FU alone decreased height (P < 0.05; Δ = -0.5878) compared to tangential excision with triamcinolone use (n = 46). Color match improved (P < 0.05) with tangential excision plus <4 injections (Δ = -0.449) and tangential excision with delayed injections (n = 29; Δ = -0.380).Tangential excision with any 5-FU use (n = 62) had higher complication rates (4.84%) than tangential excision with triamcinolone only (n = 30; 0%) or tangential excision with 5-FU only (n = 37; 5.41%), but complication rates did not significantly differ. CO2 laser-assisted 5-FU (n = 16) complication rates (6.25%) did not significantly differ from tangential excision with 5-FU or triamcinolone. No systemic complications were identified. Recurrence rates between all groups did not differ significantly. CONCLUSIONS: Tangential excision with 5-FU monotherapy demonstrated lower scar height and improved overall scar quality, further solidifying the benefits of 5-FU. CO2 laser-assisted 5-FU delivery had similar complication rates as the other studied modalities. This pediatric study had no systemic complications and overall similar complication rates compared to adult studies. This study demonstrates the utility of 5-FU in pediatric scar therapy and provides data regarding novel approaches to difficult pediatric scar management.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Lopes K, Lance S, Harfouche C, et al. Pediatric Scar Management Using Tangential Excision With Intralesional Injections and Laser-Assisted 5-Fluorouracil Delivery. Ann Plast Surg. 2025. PMID: 40310005. doi:10.1097/SAP.0000000000004207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。